Skip to main content
. Author manuscript; available in PMC: 2022 May 7.
Published in final edited form as: Pediatr Neurol. 2019 Dec 3;104:23–29. doi: 10.1016/j.pediatrneurol.2019.11.016

TABLE 1.

Characteristics by First Treatment (Standard Only)

Characteristic Variable N (%)/Median (Q1-Q3) P

Vigabatrin (N = 52) ACTH (N = 32) Prednisolone (N = 30) All (N = 114)

Sex Female 17 (32.7) 13 (40.6) 10 (33.3) 40(35.1) 0.74
Male 35 (67.3) 19 (59.4) 20 (66.7) 74 (64.9)
Race White 40 (76.9) 23 (71.9) 17 (56.7) 80 (70.2) 0.20
Black 11 (21.2) 7 (21.9) 9 (30) 27 (23.7)
Other 1 (1.9) 2 (6.3) 4 (13.3) 7(6.1)
Abnormal development No 6(11.5) 12 (37.5) 9 (30) 27 (23.7) 0.02
Yes 46 (88.5) 20 (62.5) 21 (70) 87 (76.3)
Gestational age (weeks) 38 (35.5–40) 39 (37–40) 38.5 (34–40) 38 (36–40) 0.69
Corrected age of spasm onset (months) 6.4 (5.2–9.9) 5.8 (5–7.5) 6.1 (5–8.2) 6.3 (5–8.7) 0.57
Spasm onset to first treatment (days) 14 (5–23) 10 (4–32) 17 (9–29) 14 (5–28) 0.46
Spasm onset to diagnosis (days) 12 (2–22) 7(3–31) 15.5 (8–29) 12 (3.5–25) 0.23
Diagnosis to first treatment (days) 1 (1–2.5) 1 (1–1.5) 1 (0–1) 1 (0–2) 0.06
Prior seizures No 28 (53.9) 25 (78.1) 22 (73.3) 75 (65.8) 0.045
Yes 24 (46.2) 7 (21.9) 8 (26.7) 39 (34.2)
Etiology Genetic/metabolic 9(17.3) 4(12.5) 4 (13.3) 17 (14.9) 0.04*
Prior brain injury 24 (46.2) 13 (40.6) 10 (33.3) 47 (41.2)
MCD/other structural 15 (28.9) 3 (9.4) 6 (20) 24(21.1)
Unknown abnormal 1 (1.9) 5 (15.6) 3(10) 9 (7.9)
Unknown normal 3 (5.8) 7 (21.9) 7 (23.3) 17 (14.9)
Follow-up after first treatment (months) 19(7–41) 29.5 (16–59) 18.5 (7–40) 21 (9–49) 0.06

Abbreviations:

ACTH = Adrenocorticotropic hormone

MCD = Malformation of cortical development

Values are N (column %) or median (interquartile range).

Missing values: Age of spasm onset (N = 18), spasm onset to first treatment (N = 18) and spasm onset to diagnosis (N = 18).

Kruskal-Wallis tests used for continuous variables and chi-square tests used for categorical variables.

*

Fisher’s exact tests used instead of chi-square tests.

Three of 114 patients had tuberous sclerosis complex (categorized as other structural etiology); all three received vigabatrin as the first treatment.